LiXO’MalleyBW. Unfolding the action of progesterone receptors. J Biol Chem. 2003;278(41):39261–39264.
2.
WagenfeldASaundersPTWhitakerLCritchleyHO. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045–1054.
3.
Chabbert-BuffetNMeduriGBouchardP. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11(3):293–307.
4.
FeiteiroJMarianaMVerdeICairrãoE. Genomic and nongenomic effects of mifepristone at the cardiovascular level: a review. Reprod Sci. 2017;24(7):976–988.
5.
AckermanWEIVSummerfieldTLMesianoSSchatzFLockwoodCJKnissDA. Agonist-dependent downregulation of progesterone receptors in human cervical stromal fibroblasts. Reprod Sci. 2016;23(1):112–123.
6.
LiCLSongLPTangSY. Efficacy, safety, and acceptability of low-dose mifepristone and self-administered misoprostol for ultra-early medical abortion: a randomized controlled trial. Reprod Sci. 2017;24(5):731–737.
7.
SeongSJKimDLeeKH. Role of hormone therapy after primary surgery for endometrioma: a multicenter retrospective cohort study. Reprod Sci. 2016;23(8):1011–1018.
8.
KannanABhurkeASitruk-WareR. Characterization of molecular changes in endometrium associated with chronic use of progesterone receptor modulators: ulipristal acetate versus mifepristone. Reprod Sci. 2018;25(3):320–328.
9.
LeeSRYiKWSongJY. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod Sci. 2018;25(3):341–346.
